

**NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR DISSEMINATION IN THE UNITED STATES**



Canada House Annual General Meeting Update, Cancels Proposed Share Consolidation

Toronto – December 4, 2019 (CNW) - Canada House Wellness Group Inc. (CSE: CHV) (“**Canada House**” or the “**Company**”) announced that its Annual General Meeting (“**AGM**”) will be held on December 19, 2019 at 184 Woodstock Road, Fredericton, New Brunswick beginning at 12:30 p.m. EST. Additional details can be found in the Company’s Management Information Circular at www.sedar.com.

“To honor our founding veterans and in recognition of the fact the head office for Canada House Clinics, our clinic network is New Brunswick, we are holding our AGM in the province for the first time,” said Chris Churchill-Smith, CEO, Canada House. “This has been a demanding yet extremely eventful year for Canada House and its subsidiaries. We have reached many important milestones outlined in our strategic plan. This includes Abba Medix receiving its amended sales license from Health Canada which allows us to sell our own Abba Medix branded cannabis directly to patients and consumers.”

A note to shareholders

The agenda for the AGM originally included a special resolution authorizing the consolidation of the Company’s share capital at a ratio to a maximum of 25:1. The Company has decided not to proceed with the share consolidation at this time and intends to determine a move forward only after further consultation with its shareholders and professional advisors. Accordingly, the motion on the proposed share consolidation will not be put forth for a vote by shareholders at the AGM.

A shareholder who wishes to submit questions in advance of the AGM can do so by email to ir@canadahouse.ca.

About Canada House Wellness Group Inc.

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Canada House Wellness Group's goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit www.canadahouse.ca.

For further information, please contact:

Canada House Wellness Group Inc.

Liana Del Medico

Director of Communications & Investor Relations

416-553-3820

liana.delmedico@canadahouse.ca

Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company's clinic, production and technology businesses, its future plans, the Company's markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as "may", "will", "could", "should", "would", "likely", "possible", "expect", "intend", "estimate", "anticipate", "believe", "plan", "objective" and "continue" (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company's most recent annual and interim Management's Discussion and Analysis under "Risk and Uncertainties" as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.